GlucoTrack amends multiple warrants and notes, removing floor price reduction terms
The company disclosed a series of amendments to bridge, PIPE, and September securities tied to a September 25 registered direct offering repayment.
SEC filing
Latest
9 stories
Monday, September 28
Thursday, September 24
Glucotrack prices $3 million public offering of stock and pre-funded warrants
The Nasdaq-listed company will sell shares and warrants at $2.04 to raise gross proceeds of about $3.1 million, with closing expected September 25, 2026.
SEC filing (4)
Wednesday, September 23
Glucotrack director resigns citing conflict of interest, CEO details LT-100 plans
Board member Paul Goode stepped down September 14, 2026, and the company's CEO issued a strategic update on its therapeutics pipeline days later.
SEC filing (2)
Monday, September 14
Glucotrack stockholders approve Nasdaq-required share issuances at special meeting
Shareholders backed two proposals tied to the company's ELOC and bridge financing deals, clearing a Nasdaq rule hurdle, according to an 8-K dated September 14, 2026.
SEC filing (2)
Friday, August 28
GlucoTrack files financials for merged Lokahi Therapeutics, flags going concern doubt
An 8-K/A filed August 28, 2026 shows Lokahi had $53,186 in cash at June 30, 2026 and an accumulated deficit of $8.8 million, with auditors citing substantial doubt about its ability to continue.
SEC filing
Monday, August 10
GlucoTrack amends stock purchase agreement with White Lion Capital
The August 7, 2026 amendment changes how commitment shares are calculated and adds a true-up payment provision tied to share pricing.
SEC filing
Wednesday, August 5
Glucotrack closes $5.5 million financing tied to bridge notes and PIPE deal
The company priced a $2.0 million equity unit offering at $0.75 alongside a $3.5 million convertible note follow-on from institutional investors, both dated August 4, 2026.
SEC filing
Wednesday, July 29
GlucoTrack amends note exchange terms, changes minimum price calculation date
The company's amended agreement ties share pricing to the exchange agreement's execution date rather than each individual exchange request.
SEC filing (2)
Wednesday, July 15
Glucotrack completes business combination with Lōkahi Therapeutics
Lōkahi becomes the operating business of the combined company, with its holders set to own about 90% once preferred stock converts.
SEC filing